received Menveo and Boostrix vaccines after temperature excursion; This non-serious case was reported by a other health professional and described the occurrence of incorrect storage of drug in a 13-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number LB93L, expiry date JUN-2025) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) (batch number TD2FD, expiry date MAY-2026) for prophylaxis. On 27-AUG-2024, the patient received the 1st dose of Menveo (intramuscular, left deltoid) and the 1st dose of Boostrix (intramuscular, right deltoid). On an unknown date, an unknown time after receiving Menveo and Boostrix, the patient experienced incorrect storage of drug (Verbatim: received Menveo and Boostrix vaccines after temperature excursion). The outcome of the incorrect storage of drug was unknown. Additional Information: GSK Receipt Date: 02-DEC-2024 The patient received Menveo and Boostrix vaccines after temperature excursion, which led to an incorrect storage of drug. No adverse event were reported. This was 1 of 17 linked cases, reported by same reporter.; Sender’s Comments: US-GSK-US2024AMR153916:Original Case : US2024AMR153742 US-GSK-US2024AMR153742:Original Case : US2024AMR153742 US-GSK-US2024AMR153918:Original Case : US2024AMR153742 US-GSK-US2024AMR153919:Original Case : US2024AMR153742 US-GSK-US2024AMR153920:Original Case : US2024AMR153742 US-GSK-US2024AMR153921:Original Case : US2024AMR153742 US-GSK-US2024AMR153929:Original Case : US2024AMR153742 US-GSK-US2024AMR153923:Original Case : US2024AMR153742 US-GSK-US2024AMR153924:Original Case : US2024AMR153742 US-GSK-US2024AMR153925:Original Case : US2024AMR153742 US-GSK-US2024AMR153926:Original Case : US2024AMR153742 US-GSK-US2024AMR153927:Original Case : US2024AMR153742 US-GSK-US2024AMR153928:Original Case : US2024AMR153742 US-GSK-US2024AMR153922:Original Case : US2024AMR153742 US-GSK-US2024123268:Same reporter US-GSK-US2024AMR153919:Original Case : US2024AMR153742 US-GSK-US2024123266:Same reporter